Form 4 for PHIO Phio Pharmaceuticals Corp.
Accepted 2025-05-21 00:00:00 ET · period of report 2025-05-20 · accession 0001062993-25-009985 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-21 | 2025-05-20 | PHIO | Ferrara Robert L | Dir | P - Purchase | $1.82 | +2,500 | 13.2K | +23% | +$4,550 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock, $0.0001 par value | 2025-05-20 | P | A | 2,500 | $1.82 | 13,166 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at $1.82. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the transactions. (F3) The number of reported securities has been adjusted to reflect prior reverse stock splits. (F2) Includes shares of common stock underlying unvested restricted stock units. |